7月29日，康诺亚-B盘中下跌5.38%，报73.85港元，成交额5157.56万港元，延续前一交易日跌势。
消息面上，公司此前公告其与阿斯利康合作开发的靶向CLDN18.2抗体偶联药物CMG901全球III期临床试验CLARITY-Gastric01取得积极顶线结果，在二线及后线CLDN18.2阳性晚期胃癌患者中实现具有统计学显著性的总生存期改善。公司预计该药峰值年销售额达30亿至50亿美元。尽管数据积极，股价呈现典型利好兑现回落走势，市场或已提前消化该预期，叠加前期业绩预告扭亏为盈带动的涨幅积累，短期获利了结压力显著。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.